Pan et al. reported that male NSCLC patients with SMARCA4 mutations had a markedly worse OS than females (HR: 12.64; p = 0.002), while Liang et al.’s study highlighted a worse OS for women across a cohort of Stage IV SMARCA4-mutated patients (HR:14.2; p = 0.02) [5,26]. Here, SMARCA4 is linked to non-small cell lung carcinoma.